KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells

Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-11, Vol.7 (11), p.e50701
Hauptverfasser:	Lin, Yu-Lin, Liau, Jau-Yu, Yu, Shan-Chi, Ou, Da-Liang, Lin, Liang-In, Tseng, Li-Hui, Chang, Yih-Leong, Yeh, Kun-Huei, Cheng, Ann-Lii
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis - drug effects Apoptosis - genetics Biology Biomarkers Camptothecin - analogs & derivatives Camptothecin - pharmacology Cancer Cancer cells Cell Line, Tumor Cell Survival - drug effects Cell Survival - genetics Chemotherapy Colon Colon cancer Colonic Neoplasms - genetics Colonic Neoplasms - metabolism Colorectal cancer Colorectal carcinoma Complementation Cytometry DNA methylation DNA polymerases DNA-Binding Proteins - genetics DNA-Binding Proteins - metabolism Endonucleases - genetics Endonucleases - metabolism ERCC1 protein Flow cytometry Fluorouracil - pharmacology Genetic aspects Health aspects Humans Insurance claims Irinotecan K-Ras protein Kinases Medicine Messenger RNA Mutation Organoplatinum Compounds - pharmacology Ovarian cancer Oxaliplatin Polymerase chain reaction Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins p21(ras) ras Proteins - genetics ras Proteins - metabolism RNA-directed DNA polymerase Sensitivity Sensitivity enhancement siRNA
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!